Safety, Tolerability and PK of Intravenous (IV) ETI-204 Alone and in Presence of Ciprofloxacin in Adult Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

October 29, 2013

Primary Completion Date

April 9, 2014

Study Completion Date

April 9, 2014

Conditions
Inhalational Anthrax
Interventions
BIOLOGICAL

ETI-204

A single IV infusion of 16 mg/kg ETI-204 over 90 minutes on Day 1

DRUG

Ciprofloxacin

A single IV Infusion of 400 mg Ciprofloxacin over 60 minutes immediately following the infusion of ETI-204 on Day 1, followed by oral Ciprofloxacin (750 mg every 12 hours) on Days 2-8, and a final oral dose on the morning of Day 9.

Trial Locations (1)

66211

Quintiles, Overland Park

Sponsors
All Listed Sponsors
lead

Elusys Therapeutics

OTHER

NCT01952444 - Safety, Tolerability and PK of Intravenous (IV) ETI-204 Alone and in Presence of Ciprofloxacin in Adult Volunteers | Biotech Hunter | Biotech Hunter